Esprinet raises 2026 EBITDA Adj guidance after 8% H1 sales growth
Esprinet reported strong H1 2026 results with 8% sales growth and a 27% higher EBITDA Adj. It raised full-year guidance, citing margin improvement and working capital efficiency.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.